

RAW SEQUENCE LISTING

**The Biotechnology Systems Branch of the Scientific and Technical
Information Center (STIC) no errors detected.**

Application Serial Number: 09/734,583B
Source: 1FW/b
Date Processed by STIC: 12/27/04

ENTERED

CRF Errors Edited by the STIC Systems Branch

Serial Number: 09/734,583B

CRF Edit Date: 12/29/04
Edited by: AK

___ Realigned nucleic acid/amino acid numbers/text in cases where the sequence text "wrapped" to the next line

___ Corrected the SEQ ID NO. Sequence numbers edited were:

___ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

___ Deleted: ___ invalid beginning/end-of-file text ; ___ page numbers

___ Inserted mandatory headings/numeric identifiers, specifically:

___ Moved responses to same line as heading/numeric identifier, specifically:

Other:

Seq. 8 - changed <2117 response to "12"
Seq. 2 - added "1" after "positions" in <2237 response
Seq. 10 - inserted <2207, and <2237 after 4th line in
<2237 response

globally corrected spellings of
"bridge" and "residue"

Revised 09/09/2003



IFW16

RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

3 <110> APPLICANT: Hornik, Vered

5 <120> TITLE OF INVENTION: CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN

ANALOGS

7 <130> FILE REFERENCE: 87534-3000

9 <140> CURRENT APPLICATION NUMBER: 09/734,583B

11 <141> CURRENT FILING DATE: 2000-12-13

13 <160> NUMBER OF SEQ ID NOS: 10

15 <170> SOFTWARE: PatentIn version 3.1

17 <210> SEQ ID NO: 1

18 <211> LENGTH: 14

19 <212> TYPE: PRT

20 <213> ORGANISM: mammalian

22 <400> SEQUENCE: 1

24 Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys

25 1 5 10

28 <210> SEQ ID NO: 2

29 <211> LENGTH: 6

30 <212> TYPE: PRT

31 <213> ORGANISM: Artificial sequence

33 <220> FEATURE:

W--> 34 <221> NAME/KEY: DISULFIDE BRIDGE

35 <222> LOCATION: (1)..(1)

36 <223> OTHER INFORMATION: Cys residues at amino acid positions 1 and 6 form a disulfide bridge

38 <220> FEATURE:

39 <221> NAME/KEY: MOD_RES

40 <222> LOCATION: (3)..(3)

41 <223> OTHER INFORMATION: The Trp residue is the D isomer

43 <220> FEATURE:

44 <223> OTHER INFORMATION: Synthetic peptide

46 <400> SEQUENCE: 2

48 Cys Phe Trp Lys Thr Cys

49 1 5

52 <210> SEQ ID NO: 3

53 <211> LENGTH: 6

54 <212> TYPE: PRT

C--> 55 <213> ORGANISM: Artificial peptide

57 <220> FEATURE:

58 <221> NAME/KEY: MOD_RES

59 <222> LOCATION: (1)..(1)

60 <223> OTHER INFORMATION: N-Methyl

62 <220> FEATURE:

63 <221> NAME/KEY: MOD_RES

64 <222> LOCATION: (1)..(6)

65 <223> OTHER INFORMATION: cyclo

RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

```

67 <220> FEATURE:
68 <221> NAME/KEY: MOD_RES
69 <222> LOCATION: (3)..(3)
70 <223> OTHER INFORMATION: The Trp residue is the D isomer
72 <220> FEATURE:
73 <223> OTHER INFORMATION: Synthetic peptide
76 <400> SEQUENCE: 3
78 Ala Tyr Trp Lys Val Phe
79 1      5
82 <210> SEQ ID NO: 4
83 <211> LENGTH: 8
84 <212> TYPE: PRT
85 <213> ORGANISM: Artificial Sequence
87 <220> FEATURE:
88 <221> NAME/KEY: MOD_RES
89 <222> LOCATION: (1)..(1)
90 <223> OTHER INFORMATION: The Phe residue is a D isomer
92 <220> FEATURE:
93 <221> NAME/KEY: MOD_RES
94 <222> LOCATION: (8)..(8)
95 <223> OTHER INFORMATION: The Thr residue ends with CH2OH
97 <220> FEATURE:
W--> 98 <221> NAME/KEY: DISULFIDE BRIDGE
99 <222> LOCATION: (2)..(2)
100 <223> OTHER INFORMATION: A disulfide bridge is formed between Cys residues 2 and 7
102 <220> FEATURE:
103 <221> NAME/KEY: MOD_RES
104 <222> LOCATION: (4)..(4)
105 <223> OTHER INFORMATION: The Trp residue is a D isomer
107 <220> FEATURE:
108 <223> OTHER INFORMATION: Synthetic peptide
111 <400> SEQUENCE: 4
113 Phe Cys Phe Trp Lys Thr Cys Thr
114 1      5
117 <210> SEQ ID NO: 5
118 <211> LENGTH: 7
119 <212> TYPE: PRT
120 <213> ORGANISM: Artificial Sequence
122 <220> FEATURE:
W--> 123 <221> NAME/KEY: DISULFIDE
124 <222> LOCATION: (2)..(2)
125 <223> OTHER INFORMATION: A Disulfide Bridge is formed between the Cys residues at
position
126      2 and 6
128 <220> FEATURE:
129 <221> NAME/KEY: MOD_RES
130 <222> LOCATION: (1)..(1)
131 <223> OTHER INFORMATION: The Phe residue is a D isomer
133 <220> FEATURE:
134 <221> NAME/KEY: MOD_RES

```

RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

135 <222> LOCATION: (4)..(4)
 136 <223> OTHER INFORMATION: The Trp residue is a D isomer
 138 <220> FEATURE:
 139 <221> NAME/KEY: MOD_RES
 140 <222> LOCATION: (7)..(7)
 141 <223> OTHER INFORMATION: The Thr residue ends with N2H
 143 <220> FEATURE:
 144 <223> OTHER INFORMATION: Synthetic peptide
 147 <400> SEQUENCE: 5
 149 Phe Cys Phe Trp Lys Cys Thr
 150 1 5
 153 <210> SEQ ID NO: 6
 154 <211> LENGTH: 8
 155 <212> TYPE: PRT
 156 <213> ORGANISM: Artificial sequence
 158 <220> FEATURE:
 159 <221> NAME/KEY: MISC_FEATURE
 160 <222> LOCATION: (1)..(1)
 161 <223> OTHER INFORMATION: is a gamma amino butyric acid, diamino butyric acid, Gly,
 beta-Al
 162 a, 5-amino pentanoic acid or amino hexanoic acid; Residue 1 is
 163 bridged to Residue 8; Residue 1 also begins with a hydrogen, or a
 164 mono- or di- saccharide attached
 166 <220> FEATURE:
 167 <221> NAME/KEY: MISC_FEATURE
 168 <222> LOCATION: (2)..(2)
 169 <223> OTHER INFORMATION: is (D) or (L) Phe or Tyr
 171 <220> FEATURE:
 172 <221> NAME/KEY: MISC_FEATURE
 173 <222> LOCATION: (3)..(3)
 174 <223> OTHER INFORMATION: is (D) or (L)-Trp, or (L)-Phe, (D)- or (L)-lNal or (D) or
 175 (L)-2Nal, or Tyr
 177 <220> FEATURE:
 178 <221> NAME/KEY: MISC_FEATURE
 179 <222> LOCATION: (4)..(4)
 180 <223> OTHER INFORMATION: is (D) or (L)-Trp
 182 <220> FEATURE:
 183 <221> NAME/KEY: MISC_FEATURE
 184 <222> LOCATION: (5)..(5)
 185 <223> OTHER INFORMATION: is (D) or (L)-Lys
 187 <220> FEATURE:
 188 <221> NAME/KEY: MISC_FEATURE
 189 <222> LOCATION: (6)..(6)
 190 <223> OTHER INFORMATION: is Thr, Gly, Abu, Ser, Cys, Val, (D) or (L)-Ala, or (D)- or
 191 (L)-Ala, or Tyr
 193 <220> FEATURE:
 194 <221> NAME/KEY: MISC_FEATURE
 195 <222> LOCATION: (7)..(7)
 196 <223> OTHER INFORMATION: is (D) or (L)-Phe, or (D)- or (L)-Ala, Nle, or Cys
 198 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

```

199 <221> NAME/KEY: MISC_FEATURE
200 <222> LOCATION: (8)..(8)
201 <223> OTHER INFORMATION: is Gly, Val, Leu, (D) or (L)-Phe, or 1Nal or 2Nal; with a
202     terminal carboxy acid, amide or alcohol group
204 <220> FEATURE:
205 <223> OTHER INFORMATION: Synthetic peptide
208 <400> SEQUENCE: 6
W--> 210 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
211 1 5
214 <210> SEQ ID NO: 7
215 <211> LENGTH: 7
216 <212> TYPE: PRT
217 <213> ORGANISM: Artificial Sequence
219 <220> FEATURE:
220 <221> NAME/KEY: MISC_FEATURE
221 <222> LOCATION: (1)..(1)
222 <223> OTHER INFORMATION: is (D)- or (L)-Phe, or (D)- or (L)-Ala; wherein Residue 1 is
223     bridged to Residue 6 a bridging group composed of 1 to 5 methyl
224     spacers connected to an amide, thioether, thioester, or disulfide,
225     followed by 1 to 5 methyl spacers
227 <220> FEATURE:
228 <221> NAME/KEY: MISC_FEATURE
229 <222> LOCATION: (2)..(2)
230 <223> OTHER INFORMATION: is Tyr or (D)- or (L)-Phe
232 <220> FEATURE:
233 <221> NAME/KEY: MISC_FEATURE
234 <222> LOCATION: (3)..(3)
235 <223> OTHER INFORMATION: is (D)- or (L)-Trp, (D)- or (L)-1Nal, or (D)- or (L)-2Nal
237 <220> FEATURE:
238 <221> NAME/KEY: MISC_FEATURE
239 <222> LOCATION: (5)..(5)
240 <223> OTHER INFORMATION: is Thr, Val, Ser, or Cys
242 <220> FEATURE:
243 <221> NAME/KEY: MISC_FEATURE
244 <222> LOCATION: (6)..(6)
245 <223> OTHER INFORMATION: is Gly or (D)- or (L)-Phe
247 <220> FEATURE:
248 <221> NAME/KEY: MISC_FEATURE
249 <222> LOCATION: (7)..(7)
250 <223> OTHER INFORMATION: is Thr, GABA, (D)- or (L)-1Nal, (D)- or (L)-2Nal, or (D)- or
251     (L)-Phe
253 <220> FEATURE:
254 <223> OTHER INFORMATION: Synthetic peptide
257 <400> SEQUENCE: 7
W--> 259 Xaa Xaa Xaa Lys Xaa Xaa Xaa
260 1 5
263 <210> SEQ ID NO: 8
264 <211> LENGTH: 12
265 <212> TYPE: PRT

```

RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

266 <213> ORGANISM: Artificial Sequence
268 <220> FEATURE:
269 <221> NAME/KEY: MISC_FEATURE
270 <222> LOCATION: (1)..(1)
271 <223> OTHER INFORMATION: is absent or is any amino acid
273 <220> FEATURE:
274 <221> NAME/KEY: MISC_FEATURE
275 <222> LOCATION: (2)..(2)
276 <223> OTHER INFORMATION: is absent or is any amino acid
278 <220> FEATURE:
279 <221> NAME/KEY: MISC_FEATURE
280 <222> LOCATION: (3)..(3)
281 <223> OTHER INFORMATION: is absent or is any amino acid
283 <220> FEATURE:
284 <221> NAME/KEY: MISC_FEATURE
285 <222> LOCATION: (4)..(4)
286 <223> OTHER INFORMATION: is absent or is any amino acid
288 <220> FEATURE:
289 <221> NAME/KEY: MISC_FEATURE
290 <222> LOCATION: (5)..(5)
291 <223> OTHER INFORMATION: is 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or
292 (D)- or (L)-Phe
294 <220> FEATURE:
295 <221> NAME/KEY: MISC_FEATURE
296 <222> LOCATION: (6)..(7)
297 <223> OTHER INFORMATION: may be absent, or are independently Gly, Tyr, 1Nal, 2Nal,
298 Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe
300 <220> FEATURE:
301 <221> NAME/KEY: MISC_FEATURE
302 <222> LOCATION: (8)..(8)
303 <223> OTHER INFORMATION: (D)- or (L)-Trp
305 <220> FEATURE:
306 <221> NAME/KEY: MISC_FEATURE
307 <222> LOCATION: (9)..(9)
308 <223> OTHER INFORMATION: (D)- or (L)-Lys
310 <220> FEATURE:
311 <221> NAME/KEY: MISC_FEATURE
312 <222> LOCATION: (10)..(10)
313 <223> OTHER INFORMATION: is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-Ala, or
314 (D)- or (L)-Phe
316 <220> FEATURE:
317 <221> NAME/KEY: MISC_FEATURE
318 <222> LOCATION: (11)..(11)
319 <223> OTHER INFORMATION: is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe
321 <220> FEATURE:
322 <221> NAME/KEY: MISC_FEATURE
323 <222> LOCATION: (12)..(12)
324 <223> OTHER INFORMATION: is absent or is Val, Thr, 1Nal or 2Nal
326 <220> FEATURE:

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/734,583B

DATE: 12/28/2004
TIME: 16:29:43

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\12282004\I734583B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:6; Xaa Pos. 1,2,3,4,5,6,7,8
Seq#:7; Xaa Pos. 1,2,3,5,6,7
Seq#:8; Xaa Pos. 1,2,3,4,5,6,7,8,9,10,11,12
Seq#:9; Xaa Pos. 1,2,3,4,5,6,7
Seq#:10; Xaa Pos. 1,2,3,4,5,6,7

VERIFICATION SUMMARY

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:43

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

L:34 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2
L:55 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3
L:98 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
L:123 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
L:210 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:259 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:332 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:400 M:283 W: Missing Blank Line separator, <220> field identifier
L:439 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0



IFW16

RAW SEQUENCE LISTING

DATE: 12/27/2004

PATENT APPLICATION: US/09/734,583B

TIME: 12:16:46

Input Set : A:\87534-3000.txt

Output Set: N:\CRF4\12272004\I734583B.raw

3 <110> APPLICANT: Hornik, Vered

5 <120> TITLE OF INVENTION: CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN

ANALOGS

7 <130> FILE REFERENCE: 87534-3000

9 <140> CURRENT APPLICATION NUMBER: 09/734,583B

11 <141> CURRENT FILING DATE: 2000-12-13

13 <160> NUMBER OF SEQ ID NOS: 10

15 <170> SOFTWARE: PatentIn version 3.1

Does Not Comply
Corrected Diskette Needed

ERRORED SEQUENCES

263 <210> SEQ ID NO: 8

264 <211> LENGTH: 912

265 <212> TYPE: PRT

266 <213> ORGANISM: Artificial Sequence

268 <220> FEATURE:

269 <221> NAME/KEY: MISC_FEATURE

270 <222> LOCATION: (1)..(1)

271 <223> OTHER INFORMATION: is absent or is any amino acid

273 <220> FEATURE:

274 <221> NAME/KEY: MISC_FEATURE

275 <222> LOCATION: (2)..(2)

276 <223> OTHER INFORMATION: is absent or is any amino acid

278 <220> FEATURE:

279 <221> NAME/KEY: MISC_FEATURE

280 <222> LOCATION: (3)..(3)

281 <223> OTHER INFORMATION: is absent or is any amino acid

283 <220> FEATURE:

284 <221> NAME/KEY: MISC_FEATURE

285 <222> LOCATION: (4)..(4)

286 <223> OTHER INFORMATION: is absent or is any amino acid

288 <220> FEATURE:

289 <221> NAME/KEY: MISC_FEATURE

290 <222> LOCATION: (5)..(5)

291 <223> OTHER INFORMATION: is 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe

294 <220> FEATURE:

295 <221> NAME/KEY: MISC_FEATURE

296 <222> LOCATION: (6)..(7)

297 <223> OTHER INFORMATION: may be absent, or are independently Gly, Tyr, 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe

300 <220> FEATURE:

301 <221> NAME/KEY: MISC_FEATURE

pp 1, 3-5

RAW SEQUENCE LISTING

DATE: 12/27/2004

PATENT APPLICATION: US/09/734,583B

TIME: 12:16:46

Input Set : A:\87534-3000.txt

Output Set: N:\CRF4\12272004\I734583B.raw

302 <222> LOCATION: (8)..(8)
303 <223> OTHER INFORMATION: (D)- or (L)-Trp
305 <220> FEATURE:
306 <221> NAME/KEY: MISC_FEATURE
307 <222> LOCATION: (9)..(9)
308 <223> OTHER INFORMATION: (D)- or (L)-Lys
310 <220> FEATURE:
311 <221> NAME/KEY: MISC_FEATURE
312 <222> LOCATION: (10)..(10)
313 <223> OTHER INFORMATION: is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-Ala, or
314 (D)- or (L)-Phe
316 <220> FEATURE:
317 <221> NAME/KEY: MISC_FEATURE
318 <222> LOCATION: (11)..(11)
319 <223> OTHER INFORMATION: is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe
321 <220> FEATURE:
322 <221> NAME/KEY: MISC_FEATURE
323 <222> LOCATION: (12)..(12)
324 <223> OTHER INFORMATION: is absent or is Val, Thr, 1Nal or 2Nal
326 <220> FEATURE:
327 <223> OTHER INFORMATION: Synthetic peptide
330 <400> SEQUENCE: 8
W--> 332 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
E--> 333 1 5 10

09/734,583B

3

<210> 2
<211> 6
<212> PRT
<213> Artificial sequence

<220>

<221> DISULFIDE BRIDGE

<222> (1)..(1)

<223> Cys residues at amino acid positions and 6 form a disulfide bridge

✓ insert "1"

09/734,583B

4

<222> (1)..(1)
 <223> (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala; Residue 1 is connected to Residue 7 by a bridge comprised of 1 to 5 methylene spacers connected to an amide, thioether, thioester, or disulfide, followed by 1 to 5 methylene spacers

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala;

<220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> is absent or is (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> is (D)- or (L)-Tyr

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> is (D)- or (L)-Lys

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> is absent or is Thr, Val, Cys or (D)- or (L)-Ala

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> is a (D)- or (L)-Phe, Cys, or (D)- or (L)-Ala

<220>
 <223> Synthetic peptide

<400> 9

Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5

<210> 10
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> is absent or is (D)- or (L)-Phe or Ala; the bridge is connected to Residue 1 or 2 and Residue 6 or 7, wherein the bridge is comprised of 1 to 5 methylene spacers connected to an amide, thioether, thioester, or disulfide, followed by 1 to 5 methylene

see p. 5

*<223> response has a maximum
of 4 lines*

09/734,583B

5

*insert
→
insert
→*

<220>

<223> spacers

*insert <220> after 4th line
and <223> at beginning of 5th line*

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> is (D)- or (L)-Phe or Ala, Tyr

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> is (D)- or (L)-Trp

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> is (D)- or (L)-Lys

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> is Thr, Ala, Val, or Cys

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> is absent or is (D)- or (L)-Phe, Ala, or Cys

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> is absent or is Thr or Thr reduced to an alcohol

<220>

<223> Synthetic peptide

<400> 10

Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

5

VERIFICATION SUMMARY

DATE: 12/27/2004

PATENT APPLICATION: US/09/734,583B

TIME: 12:16:47

Input Set : A:\87534-3000.txt

Output Set: N:\CRF4\12272004\I734583B.raw

L:34 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2
L:55 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3
L:98 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
L:123 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
L:210 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:259 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:332 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:333 M:252 E: No. of Seq. differs, <211> LENGTH:Input:9 Found:12 SEQ:8
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:400 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:438 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0